EPM fires some questions with Neil Ward, PacBio, to learn of the trends of 2023, and how its HiFi genome sequencing technology will be used in collaboration with Boston Children's Hospital to uncover novel mutations in rare paediatric diseases.
Penelope Drake, Ph.D., head of R&D, Bioconjugates, Catalent, highlights the potential of anti-body-drug conjugates in paving a way to innovation in oncology treatments.
Daniel Samson, head of oligonucleotides at Bachem, gives some insight into the challenges faced when manufacturing on a large scale to meet growing demand.
Birmingham Biotech announced new evidence from the University of Birmingham that shows NoriZite Nasal Spray can block the infection of the Omicron variant of SARS-CoV-2 in lab-based tests.
Here Dr. Thomas Kendall, application specialist at crystallisation and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened.
Shafique Virani, chief corporate development officer and interim chief medical officer, Recursion, delves into digital transformation within drug discovery and the power of AI-enabled platforms in the future of therapeutics.
Abbie Fisher, associate at European Intellectual Property Firm, Withers & Rogers, discusses patenting a new frontier in personalised medicine with AI-powered biomarker discovery.
Rebekah Jordan sat down with Lynn Durham, CEO & founder of STALICLA, to discuss STALICLA’s recent partnership with Evgen Pharma that aims bring a therapeutic option to currently underserved patients with neurodevelopmental disorders (NDDs).
Here Dr. Carmen Guguta, global head of business development and marketing at crystallisation technology provider Technobis Crystallization Systems, explains how new technology is streamlining crystallisation research.
Particle Works launches its second platform, the Automated Library Synthesis (ALiS) System, enabling automation and high-throughput screening of lipid nanoparticle (LNP) formulations and mRNA candidates in early-stage drug development.
Lisa Caralli, Science and Technology director, Pharmaceutics, Catalent, discusses the methods that formulation scientists can undertake on small quantities of API to achieve the greatest possible results to progress through drug product development.
Henk de Wilde, chief operating officer and R&D Director, iQure Pharma discusses how better understanding of pain is helping researchers to develop novel therapeutics as non-opioid alternatives to manage neuropathic pain.
